Aisha Hasan

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Repeated courses of rituximab in chronic ITP: Three different regimens
    Aisha Hasan
    Division of Pediatric Hematology, Children s Blood Center, NY Presbyterian Hospital and Weill Cornell Medical College and Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Hematol 84:661-5. 2009
  2. ncbi Artificial antigen presenting cells that express prevalent HLA alleles: A step towards the broad application of antigen-specific adoptive cell therapies
    Aisha N Hasan
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Discov Med 8:210-8. 2009
  3. ncbi Novel strategies for adoptive therapy following HLA disparate transplants
    RICHARD J O'REILLY
    Marrow Transplantation Program, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Best Pract Res Clin Haematol 24:381-91. 2011
  4. ncbi Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias
    Ekaterina Doubrovina
    Department of Pediatrics, Bone Marrow Transplantation Service and Division of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 120:1633-46. 2012
  5. ncbi Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants
    RICHARD J O'REILLY
    Department of Pediatrics, Memorial Sloan Kettering Cancer Institute, New York, NY, USA
    Immunol Res 38:237-50. 2007
  6. ncbi Use of humanized severe combined immunodeficient mice for human vaccine development
    Gloria C Koo
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Expert Rev Vaccines 8:113-20. 2009

Collaborators

Detail Information

Publications6

  1. ncbi Repeated courses of rituximab in chronic ITP: Three different regimens
    Aisha Hasan
    Division of Pediatric Hematology, Children s Blood Center, NY Presbyterian Hospital and Weill Cornell Medical College and Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Hematol 84:661-5. 2009
    ..Neither combining rituximab with CVP nor doubling the dose of rituximab increased the response rate...
  2. ncbi Artificial antigen presenting cells that express prevalent HLA alleles: A step towards the broad application of antigen-specific adoptive cell therapies
    Aisha N Hasan
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Discov Med 8:210-8. 2009
    ....
  3. ncbi Novel strategies for adoptive therapy following HLA disparate transplants
    RICHARD J O'REILLY
    Marrow Transplantation Program, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Best Pract Res Clin Haematol 24:381-91. 2011
    ..These approaches may thus provide new, immediately accessible resources for the generation and broad application of immune cell therapies to treat and prevent severe viral diseases post transplant...
  4. ncbi Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias
    Ekaterina Doubrovina
    Department of Pediatrics, Bone Marrow Transplantation Service and Division of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 120:1633-46. 2012
    ..This series of immunogenic epitopes of WT-1 should prove useful for immunotherapies targeting WT-1(+) malignancies...
  5. ncbi Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants
    RICHARD J O'REILLY
    Department of Pediatrics, Memorial Sloan Kettering Cancer Institute, New York, NY, USA
    Immunol Res 38:237-50. 2007
    ..New more predictable strategies are under development, which should allow such therapies to be broadly applicable...
  6. ncbi Use of humanized severe combined immunodeficient mice for human vaccine development
    Gloria C Koo
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Expert Rev Vaccines 8:113-20. 2009
    ..Human immune responses could be elicited and assessed in these humanized SCID mice upon vaccination or sensitization with allogeneic tissues. A translational model is proposed to attain preclinical data for testing human vaccines...